The short version of Peptide stability fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-11. Anything still debated is marked as such rather than presented as settled.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Cartels have used public displays of violence, including videos of executions and street banners, to spread fear and assert control. They have also committed terrorist attacks. The 2008 Morelia grenade attacks killed eight and injured more than 100 civilians celebrating Independence Day. In 2011, Los Zetas carried out an arson attack on the Casino Royale in Monterrey, killing 52 civilians. Some see these efforts as intended to sap the morale of the Mexican government; others see them as an effort to let citizens know who is winning the war. Similarly, at least one dozen Mexican norteño musicians have been murdered. Most of the victims performed narcocorridos, folk songs that tell the stories of the Mexican drug trade. On July 10, 2008, the Mexican government announced plans to nearly double the size of its Federal Police force to reduce the role of the military in combating drug trafficking.
== Reactivity == Ninhydrin exists in equilibrium with the triketone indane-1,2,3-trione, which reacts readily with nucleophiles (including water). Whereas for most carbonyl compounds, a carbonyl form is more stable than a product of water addition (hydrate), ninhydrin forms a stable hydrate of the central carbon because of the destabilizing effect of the adjacent carbonyl groups. To generate the ninhydrin chromophore [2-(1,3-dioxoindan-2-yl)iminoindane-1,3-dione], the amine must condense to give a Schiff base. The reaction of ninhydrin with secondary amines gives an iminium salt, which is also coloured, generally being yellow–orange.
Partly or completely missing collarbones. A soft spot on the top of the head where the fontanelle failed to close. Underdeveloped bones and joints. Supernumerary teeth among the permanent teeth. Unerupted permanent teeth. Bossing (bulging) of the forehead. Hypertelorism.
Ibogaine is derived from the root of Tabernanthe iboga, a plant known to exhibit hallucinogenic effects in people who consume it. It is described as having a typical dose range of 1,000 to 1,500 mg orally, with these doses producing hallucinogenic effects, and a duration of 18 to 36 hours. However, lower doses like 200 to 400 mg orally are also active and said to be hallucinogenic. In addition, very low doses of ibogaine, like 8 to 50 mg orally, have been used and reported to produce stimulant or "antidepressant" effects. The onset of the drug is 1 to 3 hours and peak effects have been described as being reached after 2 hours. With full hallucinogenic doses, ibogaine is described as having three different phases of effects. The first phase is the acute or visionary phase, which onsets after 1 to 3 hours and has a duration of 4 to 8 hours; the second phase is the evaluative or introspective phase, which starts after 4 to 8 hours and has a duration of 8 to 20 hours; and the third phase is residual stimulation, which onsets after 12 to 24 hours and has a duration of 24 to 72 hours or longer. Each of these phases is described as having distinct qualitative effects. The visionary phase is a dream-like, conscious state called oneirophrenia. Visual effects are almost always present and are often described as films or slideshows. These may be accompanied by increases in long-term visual memory, resulting in autobiographical content. Other changes to sensation and perception may occur, including auditory hallucinations or distortions. Nausea and vomiting can be severe.
Sources: en.wikipedia.org
==== Varieties ==== Koikuchi (濃口; 'thick taste'): Originating in the Kantō region, its usage eventually spread all over Japan. Over 80% of the Japanese domestic soy sauce production is of koikuchi, and can be considered the typical Japanese soy sauce. It is made from roughly equal quantities of soybean and wheat. This variety is also called kijōyu (生醤油) or namashōyu (生しょうゆ) when it is not pasteurized. Usukuchi (薄口; 'thin taste'): Almost 14% of soy sauce production is usukuchi shoyu. It is particularly popular in the Kansai region of Japan. It matures for less time than koichuchi and is both saltier and lighter in color. It is paler due to the use in its production of amazake, a sweet liquid made from fermented rice. Usukuchi is commonly used in cooking as it does not alter the color and taste of the ingredients. Tamari (たまり): Made mainly in the Chūbu region of Japan, tamari is darker in appearance and richer in flavor than koikuchi. It contains little or no wheat. Wheat-free tamari can be used by people with gluten intolerance. Tamari is more viscous than koikuchi shoyu. Of soy sauce produced in Japan, 1.5% is tamari. It is the "original" Japanese soy sauce, as its recipe is closest to the soy sauce originally introduced to Japan from China. Technically, this variety is known as miso-damari (味噌溜り), as this is the liquid that runs off miso (a soybean-based seasoning and soup base) as it matures.
A new French commander in chief and high commissioner, General Jean Marie de Lattre de Tassigny, was appointed in December 1950. With him began the construction of a defensive line of fortifications around the Red River Delta, to protect against Việt Minh incursions and against a possible Chinese invasion. It became known as the De Lattre Line. In 1950 and 1951, de Lattre implemented scorched earth tactics in an effort to limit Việt Minh access to food and other supplies. French forces burned crops in areas of Việt Minh activity. These tactics increased the anger of the Vietnamese people against the French and were a strategic failure. In late 1950 Giáp decided to go on a "general counteroffensive", seeking the final defeat of the French. On January 13, 1951, he moved the 308th and 312th Divisions, with more than 20,000 men, to attack Vĩnh Yên, 30 miles (48 km) northwest of Hanoi, which was manned by 6,000 French troops. Considered the first set-piece battle of the war, the Vietnamese saw initial success, although as the battle progressed, French aerial supremacy proved decisive as reinforcements flew in from the rest of Indochina and all available aircraft capable of dropping bombs was utilized to carry out what would be the largest aerial bombardment of the war. By noon of January 17, Giáp's troops withdrew in defeat. The Vietnamese had suffered 5,000–6,000 deaths and 500 combatants were captured. Giáp tried again to break the French defensive line, this time 20 miles (32 km) north-east of Haiphong in an attempt to cut the French access to the port city.
== Awards and recognition == Reith and her two collaborators were recognised on 28 March 1984 in an early day motion in the House of Commons, tabled by Michael Forsyth and other MPs. She was made a Commander of the Order of the British Empire (CBE) in the 2023 Birthday Honours, "for services to people with diabetes". She was given a Lifetime Achievement award at the 2024 Pride Of Britain Awards.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.